The audio of this episode may be broken.
How to fix it?
ABOUT THIS EPISODE
The FDA Compounding Incidents Program: Adverse Events Associated with Compounded Drugs from Outsourcing Facilities
English
United States
SEARCH PAST EPISODES
Search past episodes of FDA CDER Small Business and Industry Assistance (SBIA) Chronicles.
OTHER EPISODES IN THIS PODCAST
FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds
The Role of Pharmacodynamic Biomarkers in Biosimilar Drug Development
Continuous manufacturing (CM) technology has the potential to improve product quality and reliability, lower manufacturing costs, reduce waste, decrease inventory, and increase manufacturing flexibility and agility in response to product demand.
The CDER NextGen Portal (or the “Portal” for short) has made it easier than ever for regulated industry to communicate with the FDA.
Disclaimer: The podcast and artwork embedded on this page are from U.S. Food and Drug Administration, Center for Drug Evaluation and Research, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.
EDIT
Thank you for helping to keep the podcast database up to date.
